Trials / Completed
CompletedNCT00193713
Bifeprunox in the Treatment of Schizophrenia
A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bifeprunox |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2005-09-19
- Last updated
- 2015-01-16
Source: ClinicalTrials.gov record NCT00193713. Inclusion in this directory is not an endorsement.